top of page
Genetically Driven, Personalized Medicine for Autoimmune Disease
ABS is addressing one of the most critical unmet needs in autoimmune disease
For 30-50% of patients with inadequate response to standard
of care treatment
ABS is developing precision therapies to normalize or ”reset” the immune system of patients whose genetics make them resistant to successful treatment.
ABS is targeting genetically elevated soluble IL7 receptor likely to be the root cause of refractory disease
OUR VISION
Innovative treatment for the Genetically-Defined Risk Population in Multiple Autoimmune Diseases.
By targeting soluble IL7 receptor (sIL7R) a novel pathway fundamental to immune regulation, ABS is developing precision therapies for patients of various autoimmune diseases defined by the presence of the SNP and high levels of sIL7R.
bottom of page